API SUPPLIERS

API Suppliers

0

US DMFs Filed

0

CEP/COS Certifications

0

JDMFs Filed

0

Other Certificates

0

Other Suppliers

0

API REF. PRICE (USD / KG)

0

API Market Place

0

INTERMEDIATES

0

DOSSIERS // FDF

USA (Orange Book)

0

Europe

0

Canada

0

Australia

0

South Africa

0

Uploaded Dossiers

0

GLOBAL SALES (USD Million)

U.S. Medicaid

0

Annual Reports

0

FDF Market Place

0

EXCIPIENTS

0

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

0

USFDA Exclusivities

0

DIGITAL CONTENT

Blog #PharmaFlow

0

News

0

REF STANDARD

EDQM

0

USP

0

JP

0

Other Listed Suppliers

0

SERVICES

0

Full Screen View

Sosei Heptares

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Sosei Heptares to Regain Worldwide Rights to Muscarinic Agonist Programs

Details:

AbbVie has notified that it will be returning to Sosei Heptares all assets in development under the program including HTL0018318, all intellectual property licensed by Sosei Heptares to Allergan, and all clinical and preclinical data generated under the partnership.

Lead Product(s): HTL0018318

Therapeutic Area: Neurology Product Name: HTL0018318

Highest Development Status: Phase IProduct Type: Small molecule

Partner/Sponsor/Collaborator: Allergan Aesthetics

Deal Size: $3,290.0 million Upfront Cash: $125.0 million

Deal Type: Terminated January 05, 2021

ASK
US